Cargando…
Anlotinib combined with temozolomide for the treatment of patients with diffuse midline glioma: a case report and literature review
BACKGROUND: Diffuse midline glioma with a histone H3-K27M mutation is a brand-new tumor entity according to the 2016 edition of World Health Organization (WHO) classification. As diffuse midline gliomas are aggressive and incurable brain tumors, characterized by high levels of intrinsic and acquired...
Autores principales: | Feng, Yiping, Xu, Qingsheng, Fang, Minwei, Hu, Chi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641137/ https://www.ncbi.nlm.nih.gov/pubmed/36388022 http://dx.doi.org/10.21037/tcr-22-1073 |
Ejemplares similares
-
Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis
por: Yang, Qunying, et al.
Publicado: (2021) -
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018) -
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
por: Abe, Hideaki, et al.
Publicado: (2020) -
Immunotherapy approaches for the treatment of diffuse midline gliomas
por: Bernstock, Joshua D., et al.
Publicado: (2022) -
Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report
por: Wang, Qiang, et al.
Publicado: (2021)